Miracor Medical Systems, an Awans, Belgium-based medical device company developing innovative solutions to treat severe heart diseases, raised €25m in Series D financing round.
The round – which includes equity and debt, as well as non-dilutive cash advance granted by Wallonia’s Government – was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating in this financing round were the new Belgian and Walloon public investors SFPI, SRIW and Meusinvest, as well as the existing investors Earlybird Venture Capital, Delta Partners, SHS Gesellschaft für Beteiligungsmanagement, Biomed Invest and Peppermint Venture Partners.
The company, which is relocating from Austria to Belgium, intends to use the funds to further develop and commercialize the PiCSO® Impulse System.
Led by Olivier Delporte, CEO, Miracor Medical provides innovative solutions for the treatment of severe cardiac diseases, aiming at short-term and long-term clinical outcomes and reducing associated disease cost. Its PiCSO therapy is a coronary sinus intervention designed to reduce infarct size, improve cardiac function and potentially reduce myocardial infarction.